Clinical Trials Logo

Scars clinical trials

View clinical trials related to Scars.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04593706 Not yet recruiting - Keloid Clinical Trials

Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids and hypertrophic Scars)

NCT ID: NCT03850119 Not yet recruiting - Hypertrophic Scar Clinical Trials

Nanofat on Wound Healing and Scar Formation

NFWHSF
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness and safety of intradermal injection of Nanofat on wound healing and scar formation.

NCT ID: NCT02620475 Not yet recruiting - Scars Clinical Trials

A Randomized Split Scar Study of Suture Safe Treatment of Surgical Wounds to Minimize Scaring

Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect SutureSafe dressings have on reducing scarring from an incision following an elective abdominoplasty (tummy tuck) procedure. The scar will be evaluated using subjective clinical assessment criteria. Each participant in the study will serve as a control and experiential study, since have of the incision will be treated with the gold standard of care and the other half with SutureSafe dressings.

NCT ID: NCT02590042 Not yet recruiting - Scars Clinical Trials

Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction

Start date: October 2017
Phase: Phase 1
Study type: Interventional

A single-arm, open-labeled, single-center, descriptive and exploratory safety trial using ADSC-SVF-002. ADSC-SVF-002 is an autologous adipose derived stem cell (ADSC)-containing stromal vascular fraction (SVF) obtained from subcutaneous fat harvested by liposuction from a patient. As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection, with or without unprocessed autologous fat (fresh or cryopreserved), into soft tissue defects and abnormally healing wounds. The primary objective of the trial is to demonstrate the safety of ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.